Macrocyclic peptides active against the hepatitis C virus
申请人:Llinas-Brunet Montse
公开号:US20050080005A1
公开(公告)日:2005-04-14
Compounds of formula I:
wherein D, R
4
, R
3
, L
0
, L
1
, L
2
, R
2
and R
c
are defined herein; or a pharmaceutically acceptable salt thereof, useful as inhibitors of the HCV NS3 protease.
Compounds of formula (I):
wherein B, X, R
3
, L
0
, L
1
, L
2
, R
2
, R
1
and R
C
are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.
Compounds of formula (I):
wherein B, X, R
3
, L
0
, L
1
, L
2
, R
2
, R
1
and R
C
are defined herein. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.
The invention is related to anti-viral phosphinate compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
The invention is related to anti-viral phosphinate compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.